Steatotic liver disease (commonly called fatty liver disease) progresses silently. Even in the absence of noticeable symptoms ...

Chronic liver disease (CLD) is responsible for significant morbidity and mortality. Most liver-related outcomes occur in people with advanced CLD, yet liver disease can be asymptomatic until the late ...

A research team from the Department of Medicine III at MedUni Vienna and University Hospital Vienna has conducted a large-scale study showing the important value of repeated liver assessments by a ...

New European and Latin American guidelines on the use of noninvasive tests for liver evaluation are the first to specifically address an approach that has become the standard in much of the developed ...

On Thursday, the Food and Drug Administration announced its approval of the first ever therapeutic treatment targeting metabolic dysfunction-associated steatohepatitis (MASH). This represents a ...

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal ...

WALTHAM, Mass., Feb. 26, 2024 /PRNewswire/ -- More than 100 million people in the U.S. are affected by some form of liver disease, but only 4.5 million adults have been diagnosed with the condition.

On Friday, August 15, the FDA approved Wegovy (semaglutide) as the first-ever GLP-1 therapy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) — a pivotal moment in the fight ...

Myosteatosis, the pathological infiltration of fat into skeletal muscle, is increasingly recognized as a key predictor of ...

New analysis shows alcohol-related liver disease remains a major cause of cirrhosis and liver death. Read more.